Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…
Davis Polk advised REV Group, Inc. on its $275 million initial public offering of 12,500,000 shares of common stock. The shares of common stock are listed on the New York Stock Exchange…
Davis Polk advised the sole underwriter in connection with a $201.25 million SEC-registered offering of 3,220,000 shares of common stock of Pinnacle Financial Partners, Inc. Included…
Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500 shares of common stock of Loxo Oncology, Inc. The common stock is…
Davis Polk advised the joint book-running managers in connection with the approximately $237 million primary offering of 10,000,000 shares of common stock of Summit Materials, Inc. The…
Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of Achaogen, Inc. The common stock is listed onthe NASDAQ Global…
Davis Polk advised Intesa Sanpaolo S.p.A. in connection with a consent order issued on December 15, 2016 by the New York State Department of Financial Services.
DFS Superintendent Maria T…
Davis Polk advised CSC Financial Co., Ltd. on its initial public offering and listing on the Main Board of The Stock Exchange of Hong Kong Limited and an international offering in reliance…
Davis Polk advised the sole book-running manager in connection with the $126.5 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global Market…
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $106.3 million follow-on offering of 3,864,000 shares of common stock of…